Palonosetron Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 0.25 mg/5 mL vial
Reference Brands: Aloxi(US) Palonosetron(EU)
Category:
Oncology Cancer Care
Palonosetron Injection 0.25 mg/5 mL is a 5-HT3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). Approved in both the U.S. and EU, it is particularly effective for patients undergoing highly emetogenic chemotherapy. Available in a single-dose vial for IV administration, it plays a key role in oncology B2B distribution, helping oncology centers manage chemotherapy side effects and improve patient comfort.
Palonosetron Injection is available in Injection
and strengths such as 0.25 mg/5 mL vial.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Palonosetron Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Palonosetron Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Palonosetron Injection 0.25 mg/5 mL is a 5-HT3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). It is particularly effective for patients undergoing highly emetogenic chemotherapy regimens. Approved in both the U.S. (under the brand name Aloxi) and the EU, Palonosetron is available as a single-dose 0.25 mg/5 mL vial for IV administration. This drug is essential in oncology B2B distribution, helping oncology centers and hospitals manage the side effects of chemotherapy, ensuring better patient outcomes by reducing nausea and vomiting after treatment.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing